
Merck & Co. Breaks Ground on $1 Billion Biologics Center in US
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future US home for Keytruda.
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
US Merck & Co., operating as MSD outside the US and Canada, and Chinese biopharmaceutical company Hansoh Pharma have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are primarily used for the treatment of type 2 diabetes and obesity.
US drugmaker Merck & Co. (MSD) has entered into a global license agreement to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from Chinese biotechnology company LaNova Medicines.
Mestag Therapeutics, a Cambridge, UK-headquartered biotech company working on new insights into fibroblast-immune interactions, has signed a license and collaboration agreement with US drugmaker Merck & Co., known as MSD outside of North America, to identify novel targets for the development of therapies against inflammatory diseases.
US drugmaker Merck & Co. (MSD) has agreed to acquire privately held ophthalmology-focused biotechnology company Eyebiotech (EyeBio).
MSD Animal Health, a division of Merck & Co., announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for €1.2 billion ($1.3 billion) in cash. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.
US Merck & Co., known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of $680 million.
Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to €557 million ($610 million), including an undisclosed upfront payment and contingent milestone payments.
Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where Daiichi Sankyo retains exclusive rights. Merck to pay Daiichi Sankyo up to €20.8 billion for the collaboration.
UK-based Astex Pharmaceuticals, specialized in the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced an exclusive worldwide research collaboration and license agreement with US drugmaker MSD (in the US, the company trades as Merck & Co).
A move by US drugmaker Merck & Co. to have Bayer assume all liability for lawsuits alleging that the talc-based Dr. Scholl's foot powder causes cancer has failed, at least in the first instance.
Austrian biotech Proxygen has announced a multi-year collaboration and license agreement with US drugmaker Merck & Co to identify and develop molecular glue degraders against multiple therapeutic targets. The deal could be worth up to $2.55 billion for Proxygen, based on achieving certain milestones.
US drugmaker Merck & Co. plans to add 100 new jobs as part of an expansion project at its site in Carlow, Ireland, which opened in 2008 as the company’s first vaccines facility outside of the US and currently employs 530 people.
Pfizer will invest $120 million at its plant in Kalamazoo, Michigan, to support US production of its Paxlovid (nirmatrelvir) oral antiviral treatment for Covid-19. The company said the money will fund an expansion of the active pharmaceutical ingredients (APIs) and registered starting materials (RSMs) used to produce the treatment and make it one of the world’s largest producers of APIs.
The US Food and Drug Administration (FDA) has greenlit GSK’s Priorix-branded GSK’s mumps and rubella vaccine (MMR) for people 12 months and older. It is only the second such shot to be licensed for US distribution in more than 50 years. Merck & Co’s MMR-II vaccine was approved by the FDA for the pediatric application in 1971.
US pharma group Merck & Co is collaborating with Curve Therapeutics, a privately-held UK biotech that has developed a proprietary functional drug discovery platform called Microcycle. The partners aim to discover and validate modulators of up to five therapeutic targets using Microcycle, initially for oncology and neurology indications.
With a vote of 13 to 10, the Antimicrobial Drugs Advisory Committee, an advisory panel to the US Food and Drug Administration, narrowly decided to to recommend emergency use authorization (EUA) of the Covid-19 antiviral pill molnupiravir (brand name Lagevrio) developed by US drugmaker by Merck &Co together with compatriot Ridgeback Biotherapeutics.
In response to new data published by rival Merck that downgrade earlier efficacy forecasts for its for Covid-19 oral antiviral treatment, Pfizer has announced will increase production capacity of its own antiviral pill Paxlovid as it waits for an emergency use authorization (EUA) from the FDA.
The UK has “pipped the US at the post”, as one commentator noted in typical British colloquialism on the news that the country’s health regulator MHRA has approved the Covid-19 antiviral pill molnupiravir developed by US Merck & Co together with US biotech Ridgeback Biotherapeutics.
The European Medicines Agency (EMA) has begun a rolling review of US Merck & Co’s oral antiviral molnupiravir as a candidate to treat Covid-19. The EU drugs regulator said it would assess data as soon as it becomes available, before the company submits a formal application containing all the required safety and efficacy data.
US drugs giant Merck & Co. has signed a definitive agreement to acquire publicly traded US biotech Acceleron Pharma for $180 per share, yielding a total equity value of roughly $11.5 billion. Not only because of the size of the transaction, the takeover plans are being closely watched. An activist investor or anti-trust authority could potentially upset the deal, reports suggest.
In conjunction with its American Rescue Plan, the administration of US president Joe Biden has announced its intention to spend $3 billion on building a stockpile of pharmaceuticals that can be used to treat Covid-19 and other viral threats of the future.
As India’s Covid-19 infections soar and the death toll nears 200,000, wealthier countries – including the US, UK, Germany, France and Australia – are rushing supplies of oxygen, ventilators and protective gear to the subcontinent.
With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a doubting public could shun inoculation.
US pharma giant Merck & Co is boosting its cancer drug development, adding two more collaborations – with Foghorn Therapeutics and Zymeworks.